Source comparison
MK-677 for Women Over 40: Comparison Table
Mechanism Stimulates endogenous GH release via ghrelin receptor activation Directly provides exogenous GH Restores estrogen, indirectly supports GH receptor sensitivity MK-677 restores natural pulsatile GH secretion without suppressing endogenous production. I
This comparison does not assign a generated winner or score.
- Mechanism
- Stimulates endogenous GH release via ghrelin receptor activation
- Directly provides exogenous GH
- Restores estrogen, indirectly supports GH receptor sensitivity
- MK-677 restores natural pulsatile GH secretion without suppressing endogenous production. Ideal for women seeking metabolic reset without injection protocols
- IGF-1 Elevation
- 60–90% increase at 25mg daily within 4 weeks
- 100–200% increase, dose-dependent
- Minimal direct effect on IGF-1
- MK-677 achieves clinically meaningful IGF-1 elevation comparable to low-dose recombinant GH
- Administration
- Oral, once or twice daily
- Subcutaneous injection, daily
- Oral, transdermal, or injection depending on formulation
- MK-677 eliminates injection compliance barriers. Critical for long-term adherence
- Cost (monthly)
- $80–$150 for research-grade compound
- $800–$2,000+ depending on dose
- $30–$200 depending on formulation
- MK-677 provides GH axis support at 10–20% the cost of recombinant GH
- Contraindications
- Active cancer, untreated hypothyroidism, insulin resistance, prolactinoma
- Active cancer, uncontrolled diabetes, pregnancy
- Hormone-sensitive cancer, history of blood clots, active liver disease
- MK-677 shares cancer contraindications with GH but adds insulin resistance risk. Screening bloodwork mandatory
- Primary Use Case
- Restoring GH pulse in aging populations, lean mass preservation during menopause
- Clinical GH deficiency, severe sarcopenia, wasting syndromes
- Vasomotor symptoms, bone density maintenance, vaginal atrophy
- MK-677 targets the GH decline HRT doesn't address. Best used alongside estrogen therapy in women over 40